Rhythm Pharmaceuticals (RYTM) Reports In-Line Q1 EPS, provides guidance

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q1 EPS of ($0.83), in-line with the analyst estimate of ($0.83). Revenue for the quarter came in at $60.11 million versus the consensus estimate of $55.62 million.

Financial Guidance: For the year ending December 31, 2026, Rhythm anticipates approximately $385 million to $415 million in Non-GAAP Operating Expenses. Non-GAAP Operating Expenses are derived from:

GAAP total operating expenses, inclusive of:

R&D expenses of approximately $197 million to $213 million;
SG&A expenses of approximately $188 million to $202 million; and
Excluding stock-based compensation.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Alphabet added to Dow Jones Industrial Average, Verizon dropped
• Axis Capital Limited Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Reduce (3)